At the time of the St. Gallen Conference 2017, there was still a lack of scientific data to decide for which patients adjuvant systemic therapy should be recommended after neoadjuvant systemic therapy. However, recently, the results of the CREATE-X trial  and the KATHERINE trial  have been published. In patients with a Her2-negative tumour who had residual disease after neoadjuvant chemotherapy, the CREATE-X trial showed a clinical benefit (e.g. a reduction in recurrence and longer overall survival) of adjuvant treatment with capecitabine. In the KATHERINE trial, patients with a Her2-positive tumour who had residual disease after Her2-targeted neoadjuvant therapy had more clinical benefit from adjuvant treatment with TDM-1 compared to adjuvant treatment with trastuzumab. In line with these data, 83% of the panellists endorsed adjuvant treatment with capecitabine in patients with triple-negative breast cancer and residual disease (>1 cm residual tumour in the breast and/or positive axillary lymph nodes) following neoadjuvant chemotherapy (anthracycline/taxane). Only 6% of the panellists endorsed no further therapy. In case of residual disease less than 1 cm (and no positive axillary lymph nodes) the panellists were less in favour of adjuvant chemotherapy with capecitabine; 51% of the panellists endorsed adjuvant therapy with capecitabine vs 39% of the panellists who were in favour of no further therapy. In Her2-positive tumours and residual disease in the breast (>1 cm) or in the axillary lymph nodes following a Her2-targeted neoadjuvant therapy, 94% of the panellists endorsed adjuvant chemotherapy with TDM-1. This prompted one panellist to remark that momentarily TDM-1 is not (yet) approved for this indication by EMA and/or FDA. In case of no residual disease (e.g. a pathological complete response) following neoadjuvant therapy with polychemotherapy plus trastuzumab/pertuzumab in lymph node-positive patients with a Her2-positive tumour, 38% of the panellists endorsed adjuvant therapy with trastuzumab vs 48% of the panellists preferring dual Her2-blockade adjuvant therapy with trastuzumab plus pertuzumab. In patients benefitting from a complete remission following neoadjuvant treatment with combined polychemotherapy and trastuzumab/pertuzumab in patients with a Her2-positive lymph node-negative tumour, 52% of the panellists endorsed adjuvant therapy with trastuzumab vs 26% of the panellists preferring a dual Her2-blockade adjuvant therapy with trastuzumab plus pertuzumab.
- Masuda N, et al. N Engl J Med 2017; 376: 2147-2159.
- Von Minckwitz G, et al. N Engl J Med 2019; 380: 617-628.
« Endocrine therapy in premenopausal patients Next Article
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.